Bioventus (NASDAQ:BVS) Reaches New 1-Year High on Better-Than-Expected Earnings

Bioventus Inc. (NASDAQ:BVS) shares hit a new 52-week high on Wednesday following a stronger than expected earnings report. The stock traded as high as $10.86 and last traded at $10.81, with a volume of 248668 shares trading hands. The stock had previously closed at $10.68.

The company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.09 by $0.06. The firm had revenue of $132.09 million for the quarter. Bioventus had a net margin of 4.00% and a return on equity of 28.88%. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Craig Hallum lifted their price target on shares of Bioventus from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, March 6th. Barrington Research boosted their target price on shares of Bioventus from $13.00 to $14.00 and gave the company an “outperform” rating in a research note on Friday, March 6th. Cantor Fitzgerald upgraded shares of Bioventus to a “strong-buy” rating in a research report on Wednesday, March 4th. Finally, CJS Securities began coverage on shares of Bioventus in a research report on Friday, March 27th. They set a “market outperform” rating and a $14.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $14.00.

Insider Activity at Bioventus

In related news, Director Michelle Mcmurry-Heath sold 12,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $8.79, for a total value of $105,480.00. Following the completion of the sale, the director directly owned 44,997 shares in the company, valued at approximately $395,523.63. The trade was a 21.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 33.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Bioventus

Several large investors have recently made changes to their positions in BVS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Bioventus by 7.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock valued at $211,000 after purchasing an additional 1,538 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Bioventus by 19.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 162,412 shares of the company’s stock valued at $1,486,000 after acquiring an additional 26,103 shares during the last quarter. Legal & General Group Plc boosted its stake in Bioventus by 100.9% during the 2nd quarter. Legal & General Group Plc now owns 71,409 shares of the company’s stock valued at $473,000 after acquiring an additional 35,873 shares during the last quarter. Rhumbline Advisers lifted its position in shares of Bioventus by 20.6% in the 2nd quarter. Rhumbline Advisers now owns 65,093 shares of the company’s stock worth $431,000 after buying an additional 11,133 shares during the last quarter. Finally, Marshall Wace LLP grew its position in shares of Bioventus by 32.5% during the 2nd quarter. Marshall Wace LLP now owns 211,695 shares of the company’s stock valued at $1,401,000 after buying an additional 51,951 shares during the last quarter. Institutional investors and hedge funds own 62.94% of the company’s stock.

Bioventus Trading Up 2.1%

The company has a current ratio of 1.70, a quick ratio of 1.19 and a debt-to-equity ratio of 1.22. The business’s 50-day moving average is $9.23 and its two-hundred day moving average is $8.16. The firm has a market cap of $906.34 million, a P/E ratio of 32.75 and a beta of 0.72.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non?surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low?intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.